DNA vs TYRA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 08, 2026

DNA

52.4
AI Score
VS
DNA Wins

TYRA

42.7
AI Score

Investment Advisor Scores

DNA

52score
Recommendation
HOLD

TYRA

43score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DNA TYRA Winner
Net Income -313,000 -84.86M DNA
Operating Income -315.28M -91.00M TYRA
ROE -0.1% -24.0% DNA
ROA -0.0% -22.1% DNA
Total Assets 1.12B 383.36M DNA
Cash 167.20M 73.83M DNA
Current Ratio 4.92 14.91 TYRA
Free Cash Flow -178.72M -63.80M TYRA

Relative Price Performance (Last 90 Days)

DNA 1M: -11.3% · 3M: +50.7% TYRA 1M: +5.7% · 3M: -21.8%

Current Technical Phase

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 47.0 · Price: $10.23

TYRA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -8.4%), weak momentum, RSI 41

RSI (14): 41.0 · Price: $19.77

Fundamentals Snapshot

Metric DNA TYRA
Market Cap — —
Forward P/E -3.5 -7.0
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.1% 0.0%
Gross Margin 0.7% —
Operating Margin -2.0% 0.0%
EPS -4.24 -2.63
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, DNA is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.